(Q33577236)

28 July 2017

1 reference

title

Dalcetrapib: a review of Phase II data (English)

1 reference

28 July 2017

Jennifer G Robinson

1

1 reference

PubMed ID

20465364

28 July 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Investigational Drugs

28 July 2017

1 reference

28 July 2017

19

1 reference

28 July 2017

6

1 reference

28 July 2017

795-805

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

28 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

New insights into the regulation of HDL metabolism and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Antiinflammatory properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Endothelial and antithrombotic actions of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Unique lipoprotein phenotype and genotype associated with exceptional longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.488219

10.1517/13543784.2010.488219

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

20465364